The phase 2 trial of CT-388, a once-weekly subcutaneous injection acquired as part of its $2.7 billion takeover of Carmot ...
Findings could create new opportunities to treat and study neurodegenerative diseasesScientists discovered that sugar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results